Category: Approval/Launch Region: North America · United States Company: Beigene Ltd

BeiGenes anti-PD-1 antibody tislelizumab gets China NMPA approval to treat patients with locally advanced or metastatic NSCLC

BeiGenes anti-PD-1 antibody tislelizumab gets China NMPA approval to treat patients with locally advanced or metastatic NSCLC
BeiGene, a global, science-driven biotechnology company, announced that the China National Medical Products Administration (NMPA) has approved BeiGene

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!